Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine. The company boasts complete ownership of three barium sulfate deposits in British Columbia, Canada, with two sites offering material suitable for the pharmaceutical barite industry. Furthermore, Voyageur holds stakes in a rich brine project in Utah, USA, which contains high concentrations of iodine, lithium, and bromine. The entity, which was previously named Voyageur Minerals Ltd., adopted its current moniker, Voyageur Pharmaceuticals Ltd., in December 2019. Headquartered in Calgary, Canada, the company operates from this location.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overvalued on P/FCF.